Usana Health Sciences (USNA)
Market Price (5/14/2026): $17.645 | Market Cap: $324.6 MilSector: Consumer Staples | Industry: Packaged Foods & Meats
Usana Health Sciences (USNA)
Market Price (5/14/2026): $17.645Market Cap: $324.6 MilSector: Consumer StaplesIndustry: Packaged Foods & Meats
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46% Low stock price volatilityVol 12M is 46% Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Nutritional Supplements, Organic & Natural Products, and Functional Foods & Beverages. | Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -153% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 39x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5% Key risksUSNA key risks include [1] challenges attracting and retaining customers and distributors linked to a new compensation plan, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46% |
| Low stock price volatilityVol 12M is 46% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Nutritional Supplements, Organic & Natural Products, and Functional Foods & Beverages. |
| Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -153% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 39x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5% |
| Key risksUSNA key risks include [1] challenges attracting and retaining customers and distributors linked to a new compensation plan, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Q4 2025 Earnings Miss and Profitability Decline Sparked Initial Downturn.
Usana Health Sciences reported a net loss of $1.8 million for Q4 2025, a significant decline from net earnings of $4.5 million in Q4 2024, with diluted EPS falling to -$0.10 from $0.23 in the prior year. While adjusted EPS of $0.60 beat analyst estimates, revenue of $226.2 million missed expectations by approximately $4.28 million. The quarter also saw a higher-than-expected income tax expense of $5.8 million, largely due to one-time impairment and cost realignment charges, which was about $3.1 million greater than anticipated. Following this announcement on February 17, 2026, USNA shares declined 8.0%, closing at $19.00 on February 18, 2026.
2. Continued Decline in Core Nutritional Customer Base and Overall Profitability in Q1 2026.
In the first quarter of 2026, USANA's net earnings decreased to $7.5 million from $9.4 million a year ago, representing a 20% decline, and diluted EPS fell 16% to $0.41 from $0.49. Although overall net sales remained flat year-over-year at $250.2 million and beat analyst estimates, the Core Nutritional segment experienced a 12% year-over-year decline in active customers, totaling 404,000. Additionally, Hiya Active Monthly Subscribers decreased to 186,000 from 224,000 in Q1 2025. This continued decline in the foundational customer base signals ongoing challenges in the company's core business, despite growth in the newer Rise Wellness segment, which surged 741% to $14 million.
Show more
Stock Movement Drivers
Fundamental Drivers
The -18.8% change in USNA stock from 1/31/2026 to 5/13/2026 was primarily driven by a -51.4% change in the company's Net Income Margin (%).| (LTM values as of) | 1312026 | 5132026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.70 | 17.61 | -18.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 913 | 926 | 1.5% |
| Net Income Margin (%) | 1.8% | 0.9% | -51.4% |
| P/E Multiple | 23.5 | 39.0 | 65.6% |
| Shares Outstanding (Mil) | 18 | 18 | -0.6% |
| Cumulative Contribution | -18.8% |
Market Drivers
1/31/2026 to 5/13/2026| Return | Correlation | |
|---|---|---|
| USNA | -18.8% | |
| Market (SPY) | 7.6% | 31.1% |
| Sector (XLP) | 2.0% | 36.9% |
Fundamental Drivers
The -16.7% change in USNA stock from 10/31/2025 to 5/13/2026 was primarily driven by a -76.2% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 5132026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.15 | 17.61 | -16.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 899 | 926 | 3.0% |
| Net Income Margin (%) | 3.8% | 0.9% | -76.2% |
| P/E Multiple | 11.5 | 39.0 | 238.3% |
| Shares Outstanding (Mil) | 19 | 18 | 0.6% |
| Cumulative Contribution | -16.7% |
Market Drivers
10/31/2025 to 5/13/2026| Return | Correlation | |
|---|---|---|
| USNA | -16.7% | |
| Market (SPY) | 9.5% | 29.1% |
| Sector (XLP) | 12.6% | 35.2% |
Fundamental Drivers
The -37.3% change in USNA stock from 4/30/2025 to 5/13/2026 was primarily driven by a -81.7% change in the company's Net Income Margin (%).| (LTM values as of) | 4302025 | 5132026 | Change |
|---|---|---|---|
| Stock Price ($) | 28.09 | 17.61 | -37.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 855 | 926 | 8.4% |
| Net Income Margin (%) | 4.9% | 0.9% | -81.7% |
| P/E Multiple | 12.8 | 39.0 | 205.4% |
| Shares Outstanding (Mil) | 19 | 18 | 3.8% |
| Cumulative Contribution | -37.3% |
Market Drivers
4/30/2025 to 5/13/2026| Return | Correlation | |
|---|---|---|
| USNA | -37.3% | |
| Market (SPY) | 35.4% | 36.6% |
| Sector (XLP) | 6.4% | 27.4% |
Fundamental Drivers
The -73.5% change in USNA stock from 4/30/2023 to 5/13/2026 was primarily driven by a -87.1% change in the company's Net Income Margin (%).| (LTM values as of) | 4302023 | 5132026 | Change |
|---|---|---|---|
| Stock Price ($) | 66.37 | 17.61 | -73.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 999 | 926 | -7.3% |
| Net Income Margin (%) | 6.9% | 0.9% | -87.1% |
| P/E Multiple | 18.4 | 39.0 | 111.7% |
| Shares Outstanding (Mil) | 19 | 18 | 4.5% |
| Cumulative Contribution | -73.5% |
Market Drivers
4/30/2023 to 5/13/2026| Return | Correlation | |
|---|---|---|
| USNA | -73.5% | |
| Market (SPY) | 85.5% | 32.9% |
| Sector (XLP) | 18.7% | 24.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| USNA Return | 31% | -47% | 1% | -33% | -45% | -10% | -77% |
| Peers Return | 5% | -44% | 5% | -52% | 36% | -3% | -61% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| USNA Win Rate | 67% | 17% | 67% | 33% | 33% | 40% | |
| Peers Win Rate | 58% | 33% | 46% | 38% | 42% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| USNA Max Drawdown | -18% | -53% | -35% | -39% | -49% | -25% | |
| Peers Max Drawdown | -37% | -56% | -46% | -62% | -32% | -30% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HLF, NUS, NATR, MED.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/13/2026 (YTD)
How Low Can It Go
| Event | USNA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.9% | -18.8% |
| % Gain to Breakeven | 33.2% | 23.1% |
| Time to Breakeven | 76 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -35.9% | -33.7% |
| % Gain to Breakeven | 55.9% | 50.9% |
| Time to Breakeven | 35 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -11.8% | -19.2% |
| % Gain to Breakeven | 13.4% | 23.7% |
| Time to Breakeven | 20 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -12.0% | -3.7% |
| % Gain to Breakeven | 13.7% | 3.9% |
| Time to Breakeven | 18 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -40.8% | -12.2% |
| % Gain to Breakeven | 69.0% | 13.9% |
| Time to Breakeven | 286 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -24.5% | -17.9% |
| % Gain to Breakeven | 32.5% | 21.8% |
| Time to Breakeven | 67 days | 123 days |
In The Past
Usana Health Sciences's stock fell -24.9% during the 2025 US Tariff Shock. Such a loss loss requires a 33.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | USNA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.9% | -18.8% |
| % Gain to Breakeven | 33.2% | 23.1% |
| Time to Breakeven | 76 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -35.9% | -33.7% |
| % Gain to Breakeven | 55.9% | 50.9% |
| Time to Breakeven | 35 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -40.8% | -12.2% |
| % Gain to Breakeven | 69.0% | 13.9% |
| Time to Breakeven | 286 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -24.5% | -17.9% |
| % Gain to Breakeven | 32.5% | 21.8% |
| Time to Breakeven | 67 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -50.6% | -53.4% |
| % Gain to Breakeven | 102.3% | 114.4% |
| Time to Breakeven | 421 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -41.0% | -8.6% |
| % Gain to Breakeven | 69.6% | 9.5% |
| Time to Breakeven | 2084 days | 47 days |
In The Past
Usana Health Sciences's stock fell -24.9% during the 2025 US Tariff Shock. Such a loss loss requires a 33.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Usana Health Sciences (USNA)
AI Analysis | Feedback
Here are 1-3 brief analogies for Usana Health Sciences (USNA):
- Herbalife for a wider range of science-based nutritional and personal care products.
- Nu Skin, but focused on comprehensive health and wellness solutions.
AI Analysis | Feedback
- USANA Nutritional Products (Essentials/CellSentials): Vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups.
- USANA Nutritional Products (Optimizers): Targeted supplements designed to meet cardiovascular, skeletal/structural, and digestive health needs.
- USANA Nutritional Products (Foods): Meal replacement shakes, snack bars, and other related food products.
- Celavive: A comprehensive skin care regimen catering to various skin care types and ethnicities.
- Products for Prenatal, Infant, and Young Child Age Groups: Specialized nutritional and personal care products tailored for these specific age demographics.
- Business Support Tools and Materials: Materials and online tools offered to assist associates in building their businesses and marketing products.
AI Analysis | Feedback
Major Customers of USANA Health Sciences (USNA)
USANA Health Sciences operates on a direct selling model, primarily selling its nutritional and personal care products to a global network of independent distributors, referred to as "associates." These associates then resell the products to individual consumers or consume them themselves. Therefore, USANA's direct customers are these individual associates, and the ultimate consumers of its products are individuals. As the company primarily sells products intended for individual use, here are up to three categories of individual customers that it serves:- Health and Wellness Enthusiasts: Individuals seeking to support their overall health, vitality, and specific health needs (e.g., cardiovascular, skeletal/structural, digestive health) through daily vitamin and mineral supplements, targeted optimizers, and nutritious food products like meal replacement shakes and snack bars.
- Skincare and Beauty Conscious Individuals: Consumers interested in maintaining or improving their skin health and appearance, utilizing USANA's Celavive skincare regimen tailored for various skin types and ethnicities.
- Families, Expectant Mothers, and Parents of Young Children: Customers looking for specialized nutritional support for prenatal care, infants, and young children, ensuring foundational health from an early age.
AI Analysis | Feedback
nullAI Analysis | Feedback
Kevin Guest, Chief Executive Officer and Chairman of the Board
Kevin Guest reassumed the role of Chief Executive Officer of USANA Health Sciences in January 2026, while also continuing as Chairman of the Board. He has a long history with USANA, having been involved with the company since its early days in 1992. Initially, he was a managing partner with FMG Productions, which helped produce USANA's videos and events. When FMG was brought in-house in 2004 to form USANA Studios, Mr. Guest became USANA's Vice President of Media and Events. He later became president in 2014 and Chief Executive Officer in 2015. He also served as Co-Chief Executive Officer from August 2015 to November 2016. In July 2023, he transitioned to Executive Chairman before returning to the CEO position. His entrepreneurial experience with FMG Productions provided him with a unique perspective on the company. Mr. Guest is also a mental health advocate and author of the bestselling book "All the Right Reasons."
G. Douglas Hekking, Chief Financial Officer and Principal Accounting Officer
G. Douglas Hekking serves as the Chief Financial Officer and Principal Accounting Officer of USANA Health Sciences. He was promoted to CFO in May 2017. Mr. Hekking joined USANA in 1992 and has held various management positions, including Controller from 1996 to 2005, and Vice President of Finance. He previously served as CFO from May 2011 to December 2012, stepping aside for family health matters, and then returned to a strategic role. He received a Bachelor of Science in accounting from the University of Utah and a Master of Business Administration from Brigham Young University. In June 2023, he was honored with the CXO of the Year Award by Utah Business Magazine.
Walter Noot, Chief Operating Officer
Walter Noot was appointed Chief Operating Officer in October 2019. He joined USANA in December 2016 as Chief Information Officer. Mr. Noot brings over two decades of executive leadership experience from various industries, including direct selling. Before joining USANA, he served as Chief Information Officer and Senior Vice President of Operations at Young Living Essential Oils, LC, from 2014 to 2016, where he oversaw supply chain improvements and the implementation of a new ERP system. He is responsible for global operations and information technology functions at USANA. He holds a Bachelor of Science degree in mechanical engineering from Brigham Young University.
Robert Sinnott, Chief Scientific Officer
Dr. Robert Sinnott serves as the Chief Scientific Officer of USANA Health Sciences, having joined the company in August 2016. He has more than 25 years of experience in biotechnology, life sciences, and nutrition, with 18 years specifically within the nutritional supplement industry. Prior to USANA, Dr. Sinnott held leadership roles including CEO and Chief Scientific Officer at Mannatech, Inc., and was a co-founder of Larreacorp, Ltd. He manages all aspects of global research and development at USANA. Dr. Sinnott holds a Ph.D. in Biotechnology from Arizona State University and has completed executive education programs at institutions such as Harvard Business School and the Wharton School. He also holds five patents.
Brent L. Neidig, Chief Commercial Officer
Brent L. Neidig was appointed Chief Commercial Officer in July 2023. Before this role, he served as the Executive Vice President of China at USANA Health Sciences. Mr. Neidig initially took on a leadership role at USANA as the executive director of the ethics and education team.
AI Analysis | Feedback
The key risks to Usana Health Sciences (USNA) include:- Challenges with the Direct Selling Model and Declining Active Customers: Usana Health Sciences primarily operates through a direct selling (multi-level marketing) model, which has faced significant hurdles. The company has experienced a decline in its active customer and Brand Partner base, with the recovery of sales productivity under new compensation plans identified as a major risk to the business. The multi-level marketing (MLM) channel has been in structural decline over the past five years, especially among younger consumers who prefer direct-to-consumer (DTC) brands or influencer-led commerce. This decline has contributed to decreasing active customers and net sales for Usana.
- Intense Market Competition and Evolving Consumer Behavior: The health and wellness sector is highly competitive, requiring continuous innovation and product differentiation. Usana must constantly adapt to maintain its market position and attract new customers amidst evolving consumer preferences. There is a noted shift in consumer behavior away from traditional direct selling towards other channels.
- Regulatory and Trade Uncertainties in International Markets: Operating globally, Usana is exposed to risks from changes in regulations and trade policies, particularly in key international markets like China. These uncertainties can significantly influence cross-border operations and future business plans. China, a crucial market for Usana, has presented a challenging operating environment with declining net sales in some periods, despite an increase in active customers, due to a decrease in average spend per customer.
AI Analysis | Feedback
The clear emerging threat to Usana Health Sciences is the rapid growth and increasing market share of direct-to-consumer (DTC) e-commerce brands in the nutritional, health, wellness, and personal care sectors. These digitally native brands leverage efficient online distribution, targeted digital marketing, and often transparent ingredient sourcing to reach consumers directly, bypassing traditional multi-level marketing structures. This trend directly competes with USANA's reliance on its "associates" and direct selling model by offering consumers a streamlined, often lower-cost, and more convenient purchasing experience for similar product categories.
AI Analysis | Feedback
Here are the addressable market sizes for Usana Health Sciences' main products and services: * Global Dietary Supplements Market: The global dietary supplements market was valued at approximately USD 203.56 billion in 2024 and is projected to reach around USD 435.42 billion by 2034, growing at a CAGR of about 7.9% between 2025 and 2034. North America held over 35% of the global market in 2025, with an estimated market size of USD 65.88 billion. Europe's dietary supplements market was estimated at USD 54.77 billion in 2025, and the Asia Pacific market was around USD 43.24 billion in 2025, projected to reach USD 93.04 billion by 2030. More specifically, the global vitamin and mineral supplement market is valued at USD 65.1 billion in 2026 and is projected to reach USD 110.1 billion by 2036. * Global Meal Replacement Products Market: This market was estimated at USD 21.63 billion in 2023 and is expected to grow to approximately USD 47.49 billion by 2033, with a compound annual growth rate (CAGR) of 8.18% from 2023 to 2033. Another estimate places the global market at USD 23.57 billion in 2024, growing to USD 51.99 billion by 2034, with a CAGR of 8.23% from 2025 to 2034. North America dominated the market in 2024 with a 44% share. * Global Skincare Market: The global skincare market size was valued at USD 122.11 billion in 2025 and is projected to grow to USD 227.13 billion by 2034, exhibiting a CAGR of 7.32% during the forecast period from 2026 to 2034. Asia Pacific dominated this market with a share of 51.46% in 2025. * Global Infant and Young Child Nutrition Market: The global infant nutrition market size was valued at USD 52.80 billion in 2024 and is projected to reach USD 110.15 billion by 2033, growing at a CAGR of 8.5% during the forecast period (2025–2033). Asia-Pacific is the largest shareholder in the global infant nutrition market. Another source indicates the global infant nutrition market size was approximately USD 60.1 billion in 2025 and is projected to reach around USD 158.11 billion by 2035, expanding at a CAGR of 10.15% between 2026 and 2035.AI Analysis | Feedback
Usana Health Sciences (USNA) is expected to drive future revenue growth over the next two to three years through a multi-faceted strategy that includes strategic acquisitions, continuous product innovation, the expansion of its newer brands, geographic market penetration, and the evolution of its sales model.
Drivers of Future Revenue Growth:
- Acquisition and Growth of Hiya Health Products: The acquisition of a controlling stake in Hiya Health Products in December 2024 positions USANA to significantly expand its presence in the children's wellness market. This subscription-based, direct-to-consumer (DTC) brand is projected to be a substantial contributor to net sales in fiscal years 2025 and 2026, and is accelerating USANA's shift to an omnichannel retail model.
- New Product Launches and Enhanced Formulations: USANA consistently introduces new products and upgrades existing ones within its core nutritional and personal care lines. Recent examples include the August 2024 launch of the Celavive Resurfacing Serum and Whey Protein Isolate. Furthermore, 2025 saw the introduction of innovative products such as Circulate+, Core Aminos, and Marine Collagen Peptides, alongside several new and reformulated Celavive skincare products. These innovations aim to broaden product appeal and meet evolving consumer demands.
- Expansion of "Rise Wellness" Brand: The "Rise Wellness" brand, encompassing products like Rise Bar and Protein Pop, is anticipated to experience notable growth. USANA is making strategic investments to support the expansion of this brand into new online marketplaces and retail channels, contributing to its overall sales outlook for fiscal 2026.
- Geographic Market Expansion: USANA continues to pursue international growth opportunities. A significant move was its expansion into India in the latter half of 2023, representing its first new market in five years, with expectations for long-term growth. The company is also emphasizing growth initiatives in China and exploring other new international markets.
- Revamped Brand Partner Compensation Plan and Omni-channel Strategy: To stimulate customer growth and retention, USANA implemented a revamped Brand Partner Compensation Plan in 2025. Concurrently, the company is accelerating its transition to an omni-channel sales model, which integrates its traditional direct selling approach with direct-to-consumer channels, third-party marketplaces, and retail presence, thereby aiming to expand its reach to a wider customer base.
AI Analysis | Feedback
Here is a summary of Usana Health Sciences' capital allocation decisions over the last 3-5 years:Share Repurchases
- The company's Board of Directors increased its share repurchase authorization to $150 million in September 2021, inclusive of $14 million remaining under the previous authorization.
- As of December 28, 2024, approximately $62 million remained under the current share repurchase authorization.
- From September 28, 2025, to January 3, 2026, the company did not repurchase any shares.
Share Issuance
- USANA's shares outstanding have shown a decreasing trend over the last few years, from 0.021 billion at the end of March 2021 to 0.018 billion by September 2025, indicating net repurchases rather than issuances.
- The number of shares outstanding decreased by 3.07% in one year.
Outbound Investments
- In December 2024, USANA acquired a 78.8% controlling stake in Hiya Health Products, LLC, a children's health and wellness company, for $205 million in cash. This acquisition aims to broaden USANA's reach into the direct-to-consumer channel.
- In November 2022, USANA acquired Rise Bar (now Rise Wellness) and Oola Life; the acquisition prices for these were undisclosed.
- The Hiya acquisition is expected to contribute $145 million to $160 million in net sales for fiscal year 2025 and be immediately accretive to 2025 adjusted EBITDA.
Capital Expenditures
- USANA consistently invests in research and development, allocating approximately $25 million in fiscal year 2024.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to USNA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04102026 | ELF | e.l.f. Beauty | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -1.8% | -1.8% | -6.2% |
| 04022026 | IPAR | Interparfums | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.7% | 0.7% | -0.3% |
| 04022026 | COKE | Coca-Cola Consolidated | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 5.5% | 5.5% | -5.2% |
| 03272026 | MZTI | Marzetti | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -5.0% | -5.0% | -8.6% |
| 03272026 | TAP | Molson Coors Beverage | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -1.5% | -1.5% | -2.3% |
| 11302018 | USNA | Usana Health Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | -42.2% | -39.9% | -51.9% |
| 02282017 | USNA | Usana Health Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.7% | 31.6% | -6.5% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.00 |
| Mkt Cap | 0.3 |
| Rev LTM | 926 |
| Op Inc LTM | 49 |
| FCF LTM | 23 |
| FCF 3Y Avg | 37 |
| CFO LTM | 31 |
| CFO 3Y Avg | 50 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.7% |
| Rev Chg 3Y Avg | -1.5% |
| Rev Chg Q | 0.3% |
| QoQ Delta Rev Chg LTM | 0.1% |
| Op Inc Chg LTM | 13.7% |
| Op Inc Chg 3Y Avg | -2.4% |
| Op Mgn LTM | 5.7% |
| Op Mgn 3Y Avg | 5.2% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 5.3% |
| CFO/Rev 3Y Avg | 6.4% |
| FCF/Rev LTM | 2.9% |
| FCF/Rev 3Y Avg | 4.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | 0.3 |
| P/Op Inc | 3.7 |
| P/EBIT | 3.8 |
| P/E | 5.6 |
| P/CFO | 12.7 |
| Total Yield | 5.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 9.4% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -16.3% |
| 3M Rtn | -16.7% |
| 6M Rtn | 7.3% |
| 12M Rtn | -1.9% |
| 3Y Rtn | -73.0% |
| 1M Excs Rtn | -23.6% |
| 3M Excs Rtn | -23.9% |
| 6M Excs Rtn | -3.1% |
| 12M Excs Rtn | -32.3% |
| 3Y Excs Rtn | -153.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Core nutritional | 846 | 915 | 995 | 1,186 | |
| Other | 7 | 6 | 4 | 11 | |
| Hiya direct-to-consumer | 2 | ||||
| Personal care and Skincare | 79 | ||||
| USANA Foods | 79 | ||||
| USANA Nutritionals | 964 | ||||
| Total | 855 | 921 | 999 | 1,186 | 1,135 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Core nutritional | 71 | 96 | |||
| Hiya direct-to-consumer | 0 | ||||
| Other | -5 | -3 | |||
| Total | 66 | 93 |
Price Behavior
| Market Price | $17.61 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 02/01/1995 | |
| Distance from 52W High | -50.3% | |
| 50 Days | 200 Days | |
| DMA Price | $18.23 | $22.29 |
| DMA Trend | down | down |
| Distance from DMA | -3.4% | -21.0% |
| 3M | 1YR | |
| Volatility | 49.1% | 46.3% |
| Downside Capture | 132.01 | 157.06 |
| Upside Capture | 25.79 | 48.36 |
| Correlation (SPY) | 28.8% | 35.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.11 | 1.11 | 0.89 | 0.84 | 1.32 | 0.86 |
| Up Beta | 0.36 | 0.94 | 1.26 | 0.73 | 1.23 | 0.67 |
| Down Beta | 11.22 | 1.17 | 1.70 | 1.11 | 2.44 | 1.01 |
| Up Capture | 115% | 68% | 27% | 68% | 46% | 24% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 14 | 23 | 32 | 60 | 112 | 351 |
| Down Capture | 473% | 161% | 82% | 87% | 127% | 106% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 8 | 20 | 32 | 65 | 138 | 393 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with USNA | |
|---|---|---|---|---|
| USNA | -40.9% | 46.3% | -0.99 | - |
| Sector ETF (XLP) | 7.5% | 12.7% | 0.30 | 27.4% |
| Equity (SPY) | 28.9% | 12.0% | 1.82 | 35.7% |
| Gold (GLD) | 44.6% | 26.8% | 1.35 | -1.6% |
| Commodities (DBC) | 47.8% | 18.6% | 1.96 | -18.4% |
| Real Estate (VNQ) | 11.3% | 13.5% | 0.55 | 37.9% |
| Bitcoin (BTCUSD) | -21.3% | 41.7% | -0.46 | 19.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with USNA | |
|---|---|---|---|---|
| USNA | -29.0% | 35.9% | -0.87 | - |
| Sector ETF (XLP) | 6.5% | 13.2% | 0.27 | 26.3% |
| Equity (SPY) | 13.7% | 17.1% | 0.63 | 33.3% |
| Gold (GLD) | 20.4% | 17.9% | 0.93 | 4.9% |
| Commodities (DBC) | 11.1% | 19.4% | 0.46 | -4.2% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 33.8% |
| Bitcoin (BTCUSD) | 7.5% | 55.9% | 0.35 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with USNA | |
|---|---|---|---|---|
| USNA | -5.5% | 49.8% | 0.04 | - |
| Sector ETF (XLP) | 7.7% | 14.7% | 0.39 | 22.3% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 28.5% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 2.8% |
| Commodities (DBC) | 8.3% | 17.9% | 0.38 | 5.9% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 25.9% |
| Bitcoin (BTCUSD) | 68.2% | 66.9% | 1.07 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | 3.9% | -9.9% | |
| 1/12/2026 | 3.8% | 10.5% | 8.0% |
| 10/9/2025 | -22.8% | -19.7% | -27.1% |
| 7/22/2025 | 12.4% | -4.0% | -1.3% |
| 2/25/2025 | 3.9% | -7.4% | -14.8% |
| 10/22/2024 | 6.1% | 8.2% | 14.6% |
| 7/23/2024 | -3.2% | -4.9% | -13.1% |
| 4/30/2024 | 9.7% | 7.8% | 12.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 12 | 9 |
| # Negative | 9 | 11 | 13 |
| Median Positive | 4.5% | 6.2% | 8.0% |
| Median Negative | -6.8% | -7.4% | -8.2% |
| Max Positive | 13.0% | 10.5% | 14.6% |
| Max Negative | -22.8% | -19.7% | -27.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/16/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/12/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Core Nutritional business net sales | 720.00 Mil | 742.50 Mil | 765.00 Mil | 0 | Affirmed | Guidance: 742.50 Mil for 2026 | |
| 2026 Hiya net sales | 140.00 Mil | 147.50 Mil | 155.00 Mil | 0 | Affirmed | Guidance: 147.50 Mil for 2026 | |
| 2026 Rise Wellness net sales | 65.00 Mil | 72.50 Mil | 80.00 Mil | 0 | Affirmed | Guidance: 72.50 Mil for 2026 | |
| 2026 Consolidated net sales | 925.00 Mil | 962.50 Mil | 1.00 Bil | 0 | Affirmed | Guidance: 962.50 Mil for 2026 | |
| 2026 Net earnings | 20.00 Mil | 23.50 Mil | 27.00 Mil | 0.2% | Raised | Guidance: 23.45 Mil for 2026 | |
| 2026 Diluted EPS | 1.11 | 1.28 | 1.45 | 0 | Affirmed | Guidance: 1.28 for 2026 | |
| 2026 Adjusted diluted EPS | 1.95 | 2.12 | 2.29 | 0 | Affirmed | Guidance: 2.12 for 2026 | |
| 2026 Adjusted EBITDA | 101.00 Mil | 105.00 Mil | 109.00 Mil | -0.3% | Lowered | Guidance: 105.30 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/18/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Consolidated Net Sales | 925.00 Mil | 962.50 Mil | 1.00 Bil | 4.6% | Higher New | Actual: 920.00 Mil for 2025 | |
| 2026 Core nutritional business net sales | 720.00 Mil | 742.50 Mil | 765.00 Mil | -5.8% | Lower New | Actual: 788.00 Mil for 2025 | |
| 2026 Hiya net sales | 140.00 Mil | 147.50 Mil | 155.00 Mil | 11.7% | Higher New | Actual: 132.00 Mil for 2025 | |
| 2026 Rise Wellness net sales | 65.00 Mil | 72.50 Mil | 80.00 Mil | ||||
| 2026 Net earnings | 20.30 Mil | 23.45 Mil | 26.60 Mil | 56.3% | Higher New | Actual: 15.00 Mil for 2025 | |
| 2026 Diluted EPS | 1.11 | 1.28 | 1.45 | 64.1% | Higher New | Actual: 0.78 for 2025 | |
| 2026 Adjusted diluted EPS | 1.95 | 2.12 | 2.29 | 22.5% | Higher New | Actual: 1.73 for 2025 | |
| 2026 Adjusted EBITDA | 101.30 Mil | 105.30 Mil | 109.30 Mil | 7.4% | Higher New | Actual: 98.00 Mil for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Foukas, Joshua | CHIEF LEGAL OFFICER | Direct | Sell | 5082026 | 19.82 | 3,791 | Form | ||
| 2 | Fuller, Gilbert A | Direct | Sell | 3202026 | 17.00 | 1,058 | Form | |||
| 3 | Benedict, Peter | CHIEF INFORMATION OFFICER | Direct | Sell | 3042026 | 19.38 | 4,553 | Form | ||
| 4 | Foukas, Joshua | CHIEF LEGAL OFFICER | Direct | Sell | 2232026 | 21.34 | 4,461 | Form | ||
| 5 | Mulham, David Mulham | CHIEF SALES OFFICER | Direct | Sell | 12112025 | 21.00 | 873 | 18,333 | 176,127 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.